PRISM BioLab Co. LTD (206A) AI Stock Analysis

• Market Cap: ¥7.46B
• Dividend Yield: N/A
• Average Volume (3M): 2.26M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: JP
• Employees: 27
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -7.74
• Shares Outstanding: 36,934,000
• 10 Day Avg. Volume: 1,556,930
• 30 Day Avg. Volume: 2,256,993
• PEG Ratio: 0.23
• Price to Book (P/B): 2.27
• Price to Sales (P/S): 9.06
• P/FCF Ratio: -4.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: ¥206.00 ▲(28.75% Upside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is held back primarily by weak financial performance (large ongoing losses and worsening cash burn), partially offset by strong bullish technical momentum. Valuation is constrained by negative earnings and no stated dividend yield.

Positive Factors

Debt-free balance sheet

A debt-free balance sheet materially lowers solvency risk and interest burdens, giving PRISM flexibility to fund R&D or absorb timing gaps from partnerships. This structural strength preserves strategic optionality and reduces near-term refinancing pressure while burn stabilizes.

Recent sharp revenue growth

Sustained top-line growth over two consecutive years indicates improving commercial traction for discovery services or partnered programs. Durable revenue expansion supports larger future milestone/royalty potential and validates the firm's technology-commercial fit if it continues.

Partnering/licensing model with proprietary discovery tech

A partnership/licensing model leverages external R&D funding, generating upfronts, milestones and royalties while avoiding full commercialization costs. Combined with proprietary PPI discovery capabilities, this creates a scalable, asset-light path to recurring program-driven revenue.

Negative Factors

Persistent deep net losses

Multi-year, sizeable net losses erode retained earnings and constrain internal reinvestment. Persistent unprofitability raises the probability of future equity raises or deal concessions, weakening long-term returns and making sustained operating self-sufficiency uncertain.

Worsening cash generation and accelerating burn

Volatile and accelerating negative operating and free cash flows create structural funding risk. Until cash generation stabilizes, the company will rely on partners or capital markets, which can delay programs or dilute stakeholders and constrain long-term R&D pacing.

Weak returns and volatile equity

Negative ROE and fluctuating equity reflect shareholder value erosion from ongoing losses and financing dynamics. This structural weakness can raise the company’s cost of capital, deter long-term investors, and limit ability to finance growth without adverse terms.

PRISM BioLab Co. LTD Business Overview & Revenue Model

Company Description

PRISM BioLab Co., LTD (206A) is a biotechnology company specializing in the discovery and development of small molecule drugs. The company focuses on innovative structural biology techniques to develop novel therapeutic agents targeting a range of diseases. Its core products include proprietary compounds aimed at addressing unmet medical needs in areas such as oncology and inflammatory diseases.

How the Company Makes Money

PRISM BioLab generates revenue through the development and commercialization of its proprietary drug compounds. The company earns money by licensing its technology and compounds to pharmaceutical companies, securing milestone payments and royalties based on the success of these partnerships. Additionally, PRISM BioLab may engage in collaborative research and development agreements, which provide funding and shared expertise to advance its drug candidates. The company’s revenue model is heavily reliant on successful clinical trials and securing partnerships with larger pharmaceutical firms to bring its innovations to market.

PRISM BioLab Co. LTD Financial Statement Overview

Summary

Despite sharp recent revenue growth and a debt-free balance sheet, results are dominated by deep, persistent losses and deteriorating/volatile cash flow. Negative operating and free cash flow in the latest year increases funding risk until burn stabilizes.

Income Statement

Revenue has grown sharply in the last two years (2024 and 2025 annual reports), but profitability remains deeply negative: EBIT and net income are significantly below zero in 2023–2025, implying the company is scaling revenue while operating costs remain very high. Gross margin is still positive but has compressed meaningfully versus 2022, and net margins are heavily negative despite the top-line rebound. Overall, strong growth is outweighed by persistent losses and weak earnings quality.

Balance Sheet

The balance sheet is conservatively financed with no reported debt across all periods, which lowers financial risk and provides flexibility. However, returns on equity are strongly negative in 2023–2025 due to sizable net losses, and equity has been volatile (rising from 2023 to 2024, then declining in 2025), consistent with ongoing cash burn and/or financing dynamics. Strong solvency, but weakened shareholder value creation in recent years.

Cash Flow

Cash generation has deteriorated: operating cash flow turned meaningfully negative in 2023 and again worsened in 2025 after being positive in 2024, and free cash flow is negative in every year except 2022. Free cash flow also declined sharply in 2025 versus 2024, signaling accelerating cash burn. While cash flow can differ from accounting losses, the magnitude and volatility of cash outflows increases funding risk if conditions persist.

Breakdown	Sep 2025	Sep 2024	Sep 2023	Sep 2022
Income Statement
Total Revenue	677.33M	305.62M	112.93M	554.40M
Gross Profit	269.76M	160.54M	80.31M	535.14M
EBITDA	-831.28M	-1.05B	-488.13M	67.89M
Net Income	-833.70M	-1.05B	-526.91M	72.96M
Balance Sheet
Total Assets	3.09B	4.53B	1.21B	1.74B
Cash, Cash Equivalents and Short-Term Investments	2.92B	4.39B	1.13B	1.69B
Total Debt	0.00	0.00	0.00	0.00
Total Liabilities	376.86M	1.03B	63.41M	65.23M
Stockholders Equity	2.71B	3.50B	1.15B	1.67B
Cash Flow
Free Cash Flow	-1.53B	-61.55M	-548.40M	97.25M
Operating Cash Flow	-1.47B	150.14M	-513.81M	102.96M
Investing Cash Flow	-69.01M	-244.19M	-40.38M	-7.87M
Financing Cash Flow	33.59M	3.37B	0.00	110.87M

PRISM BioLab Co. LTD Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 160.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:206A, the sentiment is Positive. The current price of 160 is below the 20-day moving average (MA) of 202.40, below the 50-day MA of 185.26, and below the 200-day MA of 192.53, indicating a neutral trend. The MACD of 5.74 indicates Positive momentum. The RSI at 51.61 is Neutral, neither overbought nor oversold. The STOCH value of 38.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:206A.

PRISM BioLab Co. LTD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4588	55 Neutral	¥82.32B	-17.30	―	―	-9.04%	13.09%
206A	54 Neutral	¥7.46B	-5.04	―	―	―	―
4594	53 Neutral	¥8.38B	-2.75	―	―	1221.43%	30.54%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4591	47 Neutral	¥5.38B	-4.17	―	―	-100.00%	7.60%
4884	42 Neutral	¥2.90B	-3.45	―	―	-9.77%	-13.86%
4598	39 Underperform	¥3.13B	-3.79	―	―	―	25.25%

PRISM BioLab Co. LTD Corporate Events

PRISM BioLab Widens Quarterly Losses and Withholds Full-Year Guidance

PRISM BioLab reported first-quarter revenue of ¥132 million for the fiscal year ending September 30, 2026, a modest year-on-year increase, but remained in the red with an operating loss of ¥284 million and a net loss of ¥285 million. Earnings per share fell to a loss of ¥7.74, while the company’s equity ratio declined from 87.6% to 80.9%, reflecting a reduction in equity as losses widened.

Total assets decreased slightly to ¥3.0 billion at the end of December 2025, indicating some balance sheet erosion early in the fiscal year. The company maintained its policy of not paying dividends, confirmed a zero-dividend forecast for the current fiscal year, and declined to issue full-year earnings guidance, citing an inability to make a reasonable estimate at this time, which adds uncertainty for investors monitoring its financial trajectory.

The most recent analyst rating on (JP:206A) stock is a Hold with a Yen193.00 price target. To see the full list of analyst forecasts on PRISM BioLab Co. LTD stock, see the JP:206A Stock Forecast page.

PRISM BioLab and Talus Bioscience Collaborate on Novel Drug Discovery

PRISM BioLab and Talus Bioscience have announced a collaboration to discover novel inhibitors for transcription factor and protein-protein interaction targets. By integrating PRISM’s chemistry platform with Talus Bio’s AI-guided regulome profiling, the partnership aims to develop first-in-class therapeutics for previously undruggable targets, potentially revolutionizing drug discovery and offering new treatment avenues for complex diseases.